System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 12 citations

PubMed: 36980495 DOI: 10.3390/diagnostics13061187

The Prognostic Significance of BRAF Gene Analysis in Children and Adolescents with Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Diagnostics (Basel) 13(6)

Authors: Eleni P Kotanidou, Styliani Giza, Vasiliki Rengina Tsinopoulou, Kosmas Margaritis, Anastasia Papadopoulou, Eleni Sakellari, Savvas Kolanis, Eleni Litou, Anastasios Serbis, Assimina Galli-Tsinopoulou

Affiliations

  • Unit of Pediatric Endocrinology and Metabolism, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, Stilponos Kyriakidi 1, 54636 Thessaloniki, Greece.
  • Department of Pediatrics, School of Medicine, Faculty of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.

Abstract

Thyroid cancer represents the prominent endocrine cancer in children. Papillary thyroid cancer (PTC) constitutes its most frequent (>90%) pediatric histological type. Mutations energizing the mitogen-activated-protein kinase (MAPK) pathway are definitely related to PTC. Its most common genetic alteration is in proto-oncogene B-Raf (BRAF). Mutated BRAF is proposed as a prognostic tool in adult PTC. We conducted a systematic review and meta-analysis evaluating the association of mutated BRAF gene and prognostic clinicopathological characteristics of PTC in children/adolescents. Systematic search for relevant studies included PubMed, MEDLINE, Scopus, clinicaltrials.gov and Cochrane Library. Pooled estimates of odds ratios for categorical data and mean difference for continuous outcomes were calculated using random/fixed-effect meta-analytic models. BRAFV600E mutation presents a pooled pediatric/adolescent prevalence of 33.12%. Distant metastasis is significantly associated with mutated BRAF gene (OR = 0.32, 95% CI = 0.16-0.61, = 0.001). Tumor size (MD = -0.24, 95% CI = -0.62-0.135, = 0.21), multifocality (OR = 1.13, 95% CI = 0.65-2.34, = 0.74), vascular invasion (OR = 1.17, 95% CI = 0.67-2.05, = 0.57), lymph node metastasis (OR = 0.92, 95% CI = 0.63-1.33, = 0.66), extra-thyroid extension (OR = 0.78, 95% CI = 0.53-1.13, = 0.19) and tumor recurrence (OR = 1.66, 95% CI = 0.68-4.21, = 0.376) presented no association or risk with BRAF mutation among pediatric/adolescent PTC. Mutated BRAF gene in children and adolescents is less common than in adults. Mutation in BRAF relates significantly to distant metastasis among children/adolescents with PTC.

MeSH

Thyroid Cancer, Papillary, Genes, Neoplasms, Thyroid Gland, Adolescent, Neoplasm Metastasis, Mutation, Prognosis, Child

Cited by